Sorafenib increased the expression of E-cadherin, and decreased the expression of N-cadherin, vimentin, snail, MMP-2 and MMP-9 in HCC cells in a dose-dependent manner (Figs. 3b, 4 and Additional file 2: Figure S3). Here, CDH1 is linked to hepatocellular carcinoma.